21043-02-7 Usage
Phenazine derivative
A class of nitrogen-containing heterocyclic compounds
1-methoxy-4-methylphenazine belongs to a group of compounds derived from phenazine, which is a nitrogen-containing ring structure.
Redox-active molecule
Capable of undergoing redox reactions
1-methoxy-4-methylphenazine can participate in reduction and oxidation reactions, making it suitable for use in electronic devices.
Organic electronic devices
Potential use in organic field-effect transistors
The redox properties of 1-methoxy-4-methylphenazine make it a candidate for applications in organic electronic devices, such as organic field-effect transistors.
Antimicrobial properties
Investigated for its ability to inhibit or kill microorganisms
1-methoxy-4-methylphenazine has been studied for its potential to combat microorganisms, which could have applications in medicine and healthcare.
Antitumor properties
Investigated for its potential to inhibit or prevent tumor growth
The compound has been researched for its possible antitumor effects, indicating potential applications in cancer treatment and therapy.
Versatile compound
Range of potential applications in various fields
1-methoxy-4-methylphenazine's unique properties make it suitable for use in a variety of fields, including medicine, materials science, and electronics.
Check Digit Verification of cas no
The CAS Registry Mumber 21043-02-7 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 2,1,0,4 and 3 respectively; the second part has 2 digits, 0 and 2 respectively.
Calculate Digit Verification of CAS Registry Number 21043-02:
(7*2)+(6*1)+(5*0)+(4*4)+(3*3)+(2*0)+(1*2)=47
47 % 10 = 7
So 21043-02-7 is a valid CAS Registry Number.
21043-02-7Relevant articles and documents
4-METHOXYACRIDINE-1-CARBOXAMIDE DERIVATIVES AND THE PHENAZINE AND OXANTHRENE ANALOGS AS PDE4-INHIBITORS FOR THE TREATMENT OF ASTHMA AND CHRONIC PULMONARY DISEASE (COPD)
-
Page/Page column 32, (2010/11/08)
The present invention relates to new Phosphodiesterase type 4 (PDE4) inhibitors of the formula (1) for treatment of asthma: Ar is a substituted or unsubstituted aryl, substituted or unsubstituted arylalkyl, substituted or unsubstituted heterocyclic ring or substituted or unsubstituted heteroaryl ring; each occurrence of L is O, S or NR 3; X and A are independently-CRaRb-,-CRa-,-C(=B)-, O, S(O)m, N or NR3; each occurrence of m is 0, 1, or 2; n is 0-4; p is 0-2; Y is-C(=B)C(=D)NR 4 or-C(=B)NR4 B is O, S or NRa; D is O, S or NRa; The other substituents are defined in the claims.
